Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade

When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. Axsome Therapeutics now meets that criteria, with an increase from 80 to 86 Tuesday.

As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.

This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.

History shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their biggest price moves.

Looking For The Best Stocks To Buy And Watch? Start Here

While Axsome Therapeutics is not near a proper buy zone right now, see if it goes on to form and break out of a proper consolidation.

Axsome Therapeutics reported 0% earnings growth last quarter, while sales growth came in at 429%.

Axsome Therapeutics earns the No. 126 rank among its peers in the Medical-Biomed/Biotech industry group. Kiniksa Pharmaceuticals and Catalyst Pharmaceuticals are also among the group's highest-rated stocks.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.